DRRX Overview

Acquisition Details: Bausch Health Companies Inc. has completed its acquisition of DURECT Corporation for $1.75 per share, totaling approximately $63 million, with potential milestone payments of up to $350 million based on future sales.

Focus on Liver Disease: The acquisition includes larsucosterol, a promising treatment for alcohol-associated hepatitis, which currently has no approved therapies and a high mortality rate; a Phase 3 trial is planned to assess its efficacy.

Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of Veritex Holdings, Provident Bancorp, and DURECT Corporation.

Veritex Holdings Sale: Veritex Holdings will be sold to Huntington Bancshares, with shareholders receiving 1.95 shares of Huntington for each share of Veritex.

Provident Bancorp Sale: Provident Bancorp's sale to NB Bancorp offers shareholders a choice between 0.691 shares of NB Bancorp stock or $13.00 in cash per share.

Legal Support Offered: Halper Sadeh LLC offers free consultations to affected shareholders and may seek increased compensation or additional disclosures on their behalf.

Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders.

Ongoing Investigations: The firm is investigating several companies including Veritex Holdings, CFSB Bancorp, Provident Bancorp, and DURECT Corporation regarding their proposed mergers and sales, with shareholder votes scheduled for September 2025.

Shareholder Benefits: Shareholders of the mentioned companies may receive cash or stock options as part of the proposed transactions, with specific terms outlined for each company.

Free Legal Consultation: Monteverde & Associates offers free consultations for shareholders concerned about these transactions, emphasizing their successful track record in class action litigation.

Financial Performance: Durect reported a GAAP earnings per share of $(0.07) and revenue of $0.45 million for Q2 2025, surpassing analyst expectations but showing a decline compared to the previous year, with a significant reliance on collaborative agreements for revenue.

Strategic Outlook: The company is focused on the development of larsucosterol for alcohol-associated hepatitis and is preparing for a merger with Bausch Health, which includes a cash offer and potential future sales milestones, while providing no forward guidance for upcoming quarters.

Quarterly Performance: Durect (DRRX) reported a quarterly loss of $0.07 per share, better than the expected loss of $0.13, and achieved revenues of $0.45 million, surpassing estimates by 39.69%. The stock has gained approximately 149.3% since the start of the year.

Future Outlook: The company's earnings outlook is mixed, with a current Zacks Rank of #3 (Hold), indicating expected performance in line with the market. Investors are advised to monitor upcoming earnings estimate revisions and industry trends that may impact stock performance.

Acquisition Details: Bausch Health will acquire DURECT Corporation for $1.75 per share, totaling approximately $63 million upfront, with potential additional payments of up to $350 million based on sales milestones, expected to close in Q3 2025.

Financial Performance: DURECT reported total revenues of $447,000 and a net loss of $2.3 million for the second quarter of 2025, showing an improvement from a net loss of $3.7 million in the same period last year.